Endocrine Abstracts (2017) 49 EP882 | DOI: 10.1530/endoabs.49.EP882

Could statin modify molecular phenotype of pituitary growth hormone-secreting tumors?

María Rosa Alhambra Expósito1,2, Paloma Moreno Moreno1,2, Concepción Muñoz Jiménez2, María Ángeles Galvez Moreno1 & Raúl Luque Huertas2

1Hospital Universitario Reina Sofía, Córdoba, Spain; 2IMIBIC, Córdoba, Spain.

Background: Acromegaly is the consequence of excessive growth hormone (GH) secretion, usually produced by a pituitary adenoma. In the last years, statins have been implicated in the response to treatment of patients with acromegaly. Although this fact is not very clear.

Objective: To analyze whether pretreatment with statins modifies the adenoma molecular phenotype of the acromegalic patients and how this changes could help to influence the response to treatment.

Material and methods: Observational study including patients with acromegaly, diagnosed at the Endocrinology and Nutrition Unit of the Hospital Reina Sofía from 2007 to 2012, in which surgery, radiology and molecular phenotyping of the adenoma was carried out.

Results: 22 patients were included (38±15 years old; 65% women). Three patients meet cure criteria. These who take statins have lower prolactin levels (9.33±2.77 mg/dl) than those who do not (54.30±52.31, P 0.005). There were no differences about molecular phenotype between two groups, it shown in Table 1. Patients meet cure criteria had taken more statins that those who had not (P 0.048).

Conclusion: Overall, our results indicate that there is a significant correlation between stantin pre-surgical treatment and the disease cure. However, there is not correlation between use of statin and molecular phenotype.

Table 1
DR2T (2L)0.0740±0.1185 (0.018±0.019)0.179±0.056 (0.119±0.329)>0.05

Article tools

My recent searches

No recent searches.